Skip to main content

SAFE GROUP – 16th Journées Thérapeutiques Interventionnelles Vertébrales et Ostéo-Articulaires: presentation of Professor Maestretti’s clinical results on the Sycamore device

16th Journées Thérapeutiques Interventionnelles Vertébrales et Ostéo-Articulaires: presentation of Professor Maestretti’s clinical results on the Sycamore device

Fleurieux-sur-l’Arbresle – France – January 7, 2025 at 6pm. Safe announces that Professor Gianluca Maestretti, Head of Orthopaedics at the Freiburg Hospital, will present his clinical results on the Sycamore device at the 16th Journées Thérapeutiques Interventionnelles Vertébrales et Ostéo-Articulaires, to be held in Nice on January 24, 2025.

Professor Maestretti, a recognized expert in orthopaedic surgery, will share his clinical observations on the use of Sycamore, an innovative device for the minimally invasive treatment of vertebral fractures. This presentation will be followed by a discussion with a panel of experts in interventional radiology, highlighting the growing impact of this technology in the field of spinal care.

This intervention is part of a wider demonstration of the device, which has already been presented at the XI MAMMI International Meeting – Diagnostic and Mini-invasive Spine Treatments – in Cagliari, Italy, from 8 to 10 December 2024. The event, organized by the Radiology Department of the Holy Trinity Hospital, was attended by internationally renowned specialists, reinforcing the recognition of the Sycamore device in the medical world.
The device, developed by Safe Orthopaedics, stands out for its ability to offer minimally invasive treatment of vertebral fractures, responding to a growing demand for solutions that are less traumatic and quicker for patients. This technology enables interventional radiologists to effectively treat vertebral fractures while minimizing risks and reducing recovery times.

The introduction of the Sycamore device into clinical practice marks a strategic step forward for Safe Orthopaedics, paving the way for a fast-growing specialty: interventional radiology. Minimally invasive treatments confirm Safe Orthopaedics’ position as a key player in the innovation of therapeutic solutions for spinal pathologies.

About Safe Group

Safe Group is a French medical technology group that brings together Safe Orthopaedics, a pioneer in ready-to-use technologies for spine pathologies, and Safe Medical (formerly LCI Medical), a medical device subcontractor for orthopedic surgeries. The group employs approximately 100 people.
Safe Orthopaedics develops and manufactures kits combining sterile implants and ready-to-use instruments, available at any time to the surgeon. These technologies are part of a minimally invasive approach aimed at reducing the risks of contamination and infection, in the interest of the patient and with a positive impact on hospitalization times and costs. Protected by 15 patent families, SteriSpineTM kits are CE marked, and FDA approved. Safe Orthopaedics has subsidiaries in the United Kingdom, Germany, the United States.
For more information: www.safeorthopaedics.com

Safe Medical produces implantable medical devices and ready-to-use instruments. It has an innovation center and two production sites in France and in Tunisia, offering numerous industrial services: industrialization, machining, finishing and sterile packaging.
For more information: www.safemedical.fr

Contacts
SAFE GROUP                                                AELYON ADVISORS
investors@safeorthopaedics.com                        safe@aelyonadvisors.fr

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.